AR073665A1 - Dsarn para el tratamiento de infeccion de virus de arn de cadenas positivas, tales como el virus de hepatitis c (hcv) - Google Patents

Dsarn para el tratamiento de infeccion de virus de arn de cadenas positivas, tales como el virus de hepatitis c (hcv)

Info

Publication number
AR073665A1
AR073665A1 ARP090103664A ARP090103664A AR073665A1 AR 073665 A1 AR073665 A1 AR 073665A1 AR P090103664 A ARP090103664 A AR P090103664A AR P090103664 A ARP090103664 A AR P090103664A AR 073665 A1 AR073665 A1 AR 073665A1
Authority
AR
Argentina
Prior art keywords
virus
treatment
positive
hcv
hepatitis
Prior art date
Application number
ARP090103664A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR073665A1 publication Critical patent/AR073665A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Abstract

La solicitud se refiere a ácidos ribonucleicos de doble cadena (dsARNs) que se dirigen a la expresion del gen de sintetasa de carbamoilfosfato 2, transcarbamilasa de aspartato, y dihidro-orotasa (CAD), y a su uso para el tratamiento de infecciones por virus de ARN de cadenas positivas, tales como el virus de hepatitis C (HCV). Cada dsARN comprende una cadena anti-sentido que tiene una secuencia de nucleotidos que es de menos de 30 nucleotidos de longitud, en general de 19 a 25 nucleotidos de longitud, y que es sustancialmente complementaria para cuando menos una parte del ARNm objetivo de CAD. Se puede emplear una pluralidad de estos dsARNs para proporcionar un beneficio terapéutico. La solicitud también se refiere a una composicion farmacéutica que comprende al dsARN junto con un vehículo farmacéuticamente aceptable, y que incluye una modalidad de suministro, tal como liposomas completamente encapsulados o complejos de lípido. La solicitud incluye además métodos para el tratamiento de las enfermedades provocadas por la infeccion por el virus de ARN de cadenas positivas utilizando las composiciones farmacéuticas: y métodos para inhibir la propagacion de los virus de ARN de cadenas positivas dentro y entre las células.
ARP090103664A 2008-09-25 2009-09-23 Dsarn para el tratamiento de infeccion de virus de arn de cadenas positivas, tales como el virus de hepatitis c (hcv) AR073665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10015508P 2008-09-25 2008-09-25

Publications (1)

Publication Number Publication Date
AR073665A1 true AR073665A1 (es) 2010-11-24

Family

ID=42026365

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103664A AR073665A1 (es) 2008-09-25 2009-09-23 Dsarn para el tratamiento de infeccion de virus de arn de cadenas positivas, tales como el virus de hepatitis c (hcv)

Country Status (4)

Country Link
US (1) US20100183704A1 (es)
AR (1) AR073665A1 (es)
TW (1) TW201018489A (es)
WO (1) WO2010034758A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240010762A (ko) * 2014-08-20 2024-01-24 알닐람 파마슈티칼스 인코포레이티드 변형 이중-가닥 rna 제제

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1896619A2 (en) * 2005-06-22 2008-03-12 Merck & Co., Inc. Targets for inhibiting hcv replication
US20080145313A1 (en) * 2006-08-30 2008-06-19 Genesis Research & Development Corporation Limited Compositions and Methods for the Treatment and Prevention of Neoplastic Disorders

Also Published As

Publication number Publication date
WO2010034758A3 (en) 2010-08-26
TW201018489A (en) 2010-05-16
WO2010034758A2 (en) 2010-04-01
US20100183704A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
AR066397A1 (es) Composiciones de arnds y metodo para el tratamiento de infeciones por el virus de papiloma humano (hpv )
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
Kim et al. Protection of shrimp (Penaeus chinensis) against white spot syndrome virus (WSSV) challenge by double-stranded RNA
EA201391394A1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
CR20220468A (es) AGENTES DE iARN PARA INFECCION CAUSADA POR EL VIRUS DE LA HEPATITIS B (Divisional 2019-0056)
PE20210921A1 (es) Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden
AR090869A1 (es) COMPOSICIONES DE ARNi DE SERPINC1 Y SUS METODOS DE USO
PE20210668A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
EA201490993A1 (ru) МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи
WO2018183808A9 (en) Antiviral therapeutic
SG171676A1 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
PE20230684A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
BR112013010525A2 (pt) tratamento de hbv
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
WO2015042308A3 (en) Rna-based hiv inhibitors
AR084319A1 (es) INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
PE20120115A1 (es) Composiciones y metodos para inhibir la expresion de genes del factor vii
ES2528010T5 (es) Métodos para detectar la presencia de patógenos intracelulares
AR079649A1 (es) Composiciones y metodos para inhibir la expresion de genes il-18
AR083445A1 (es) siARN CONTRA LA FIBROSIS
AR078921A1 (es) Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
AR073665A1 (es) Dsarn para el tratamiento de infeccion de virus de arn de cadenas positivas, tales como el virus de hepatitis c (hcv)
CL2013003466A1 (es) Construcción de arn que comprende una secuencia de segmento sentido y una antisentido del gen p0 del genoma del virus del amarilleo moderado de la remolacha (bmyv), metodo para inducir tolerancia al virus bmyv.
AR083453A1 (es) Composiciones y metodos para la inhibicion de la expresion de los genes rrm2
Song et al. RNA interference targeting glycoprotein D inhibits infectious bovine rhinotracheitis virus replication in MDBK cells

Legal Events

Date Code Title Description
FB Suspension of granting procedure